Patents by Inventor Elaine M. HURT

Elaine M. HURT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BCMA monoclonal antibody-drug conjugate
    Patent number: 11912782
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: February 27, 2024
    Assignee: MedImmune, LLC
    Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
  • COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS
    Publication number: 20220195037
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 23, 2022
    Inventors: Elaine M. HURT, Ralph MINTER, Steven RUST, Alan SANDERCOCK, Sotirios KARATHANASIS
  • Compositions and methods for inhibiting cancer stem cells
    Patent number: 11192948
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 7, 2021
    Assignee: MedImmune Limited
    Inventors: Elaine M. Hurt, Ralph Minter, Steven Rust, Alan Sandercock, Sotirios Karathanasis
  • BCMA Monoclonal Antibody-Drug Conjugate
    Publication number: 20210214460
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 15, 2021
    Inventors: Krista KINNEER, Reena VARKEY, Xiaodong XIAO, Elaine M. HURT, David TICE
  • BCMA monoclonal antibody-drug conjugate
    Patent number: 10988546
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 27, 2021
    Assignee: MedImmune, LLC
    Inventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
  • BCMA Monoclonal Antibody-Drug Conjugate
    Publication number: 20190040152
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Application
    Filed: July 31, 2018
    Publication date: February 7, 2019
    Inventors: Krista KINNEER, Reena VARKEY, Xiaodong XIAO, Elaine M. HURT, David TICE
  • COMPOSITIONS AND METHODS FOR INHIBITING CANCER STEM CELLS
    Publication number: 20180273616
    Abstract: The disclosure generally provides compositions and methods that are useful in the treatment of cancer. More specifically, the methods and compositions may be used to detect, quantify, inhibit, kill, differentiate, or eliminate cancer stem cells (CSCs) and may be used in the treatment of cancers associated with CSCs, and particularly cancers and CSCs that express LOX1.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 27, 2018
    Inventors: Elaine M. HURT, Ralph MINTER, Steven RUST, Alan SANDERCOCK, Sotirios KARATHANASIS